Equateq - Amarin Sign Supply Deal
2 June 2011
Scotland-based company Equateq has signed a long-term supply agreement with US lipid specialist, Amarin to deliver bulk Active Pharmaceutical Ingredient (API) for use in its AMR-101 product, an omega oil pharmaceutical under development for reducing cardiovascular risk.
“This is our most significant supply agreement to date, and we look forward to applying our Maxomega™ technology to deliver bulk API concentrate to Amarin,” said Equateq CEO Adam Kelliher.
“The opportunity presented by Amarin is potentially immense, and we aim to ensure they have supply chain security to meet anticipated significant demand.”
Equateq will expand its operations at its facility on the Isle of Lewis in Scotland to meet demand, where it is already manufacturing lipid APIs using its proprietary Maxomega™ technology, an industrial-scale application of HPLC.
Equateq’s technical competence, quality capabilities and regulatory experience needed to efficiently produce AMR101 to Amarin’s high quality standards helped secure the deal for the company. Equateq also have the capability to support Amarin with timely scale-up and regulatory qualification of facilities and product.
Find out more about Equateq